ZURICH, September 9, 2016 /PRNewswire/ --
Berlin Heals Holding AG, announces that it has successfully closed a second investment round in the run-up to the First-in-Man application of its ground-breaking implantable medical device for the cure of heart failure. The so called Berlin Heals C-MIC (Cardiac Microcurrent) System is a new and revolutionary method for the treatment of the disease via the direct application of electrical microcurrent to heart muscle tissue. The company's concept is in line with the recently intensified efforts in bioelectronics to use electrical signals rather than drugs to treat critical diseases.
"This funding will help us finalize all the necessary system verification activities and to begin a First-in-Man clinical trial within the next months", says Dr. Johannes Müller, initiator of the venture and CEO of Berlin Heals GmbH, the Swiss company`s ISO-certified research & development subsidiary in Berlin. "We are very thankful for the continued support by our investors. Being able to develop an active implantable medical device from scratch in less than 3 years is a great team success", adds Dr. Peter Göttel, Co-CEO of Berlin Heals GmbH.
About Berlin Heals and C-MIC
Heart failure is a chronic inflammatory disease that affects millions of patients worldwide. Since its establishment in 2014, Berlin Heals was able to demonstrate in preclinical experiments that direct microcurrent application with C-MIC is safe, has an anti-inflammatory impact and leads to a significant improvement of cardiac function as it propagates reverse remodeling of heart muscle tissue in hearts with cardiomyopathy. In fact, the new method has a realistic potential to heal heart failure, rather than just delay the progression of the disease.
The C-MIC is a small implantable device that delivers a constant but minimal electrical DC current to the heart via two electrodes attached to the organ. The preclinical trials have confirmed the efficacy of this revolutionary method, the scientific foundation of which roots in a long and intensive cooperation with the University of Vienna (Dept. of Tissue Engineering; Prof. K. Macfelda) where also most of the basic research had been performed. The electrical microcurrent remains completely undetectable to the patient, does not interfere with the heart rhythm and is expected to lead to an improvement of the heart's function in less than 6 months. No device-specific side-medication or follow-up procedures are required. "Our selected Swiss investors are very confident with the way the venture progresses. Even more so as Berlin Heals expects that its microcurrent concept can also be applied to to other internal organs with chronic inflammation", says Marko Bagaric, CEO of the Berlin Heals Holding AG. For more information: http://www.berlinheals.de.
Dr. Peter Göttel
Berlin Heals GmbH
Business & Investor Relations
Berlin Heals Holding AG
SOURCE Berlin Heals GmbH